High-dose chemotherapy with autologous stem cell transplantation spares re-irradiation for recurrent intracranial germinoma
High-dose chemotherapy with autologous stem cell transplantation spares re-irradiation for recurrent intracranial germinoma
复制标题
DOI：
10.1002/pbc.27104
复制
发表时间：
2018-08-01
影响因子：
3.2
通讯作者：
Adachi, Souichi
中科院分区：
文献类型：
--
作者：
Kubota, Hirohito;Umeda, Katsutsugu;Adachi, Souichi
回顾性分析了6例复发性颅内生殖细胞瘤患者接受大剂量化疗（HDC）联合自体干细胞移植的临床结果。在HDC之前，所有患者在基于铂和异环磷酰胺的化疗后均达到完全缓解。以美法仑为基础的预处理方案在单个周期或多个连续周期中给药。6例患者中有5例存活且无疾病，中位生存期为65个月，其中4例患者避免了再次照射。在很大一部分患者中，复发性颅内生殖细胞瘤可通过HDC治愈而无需再次照射，前提是该疾病对补救化疗仍然敏感。
The clinical outcome of high-dose chemotherapy (HDC) with autologous stem cell transplantation was retrospectively analyzed in six patients with recurrent intracranial germinoma. Prior to HDC, all patients achieved complete remission after platinum and ifosfamide-based chemotherapy. A melphalan-based conditioning regimen was administered in either a single cycle or multiple sequential cycles. Five of the six patients are alive and free from disease, with a median survival of 65 months, among which four patients avoided re-irradiation. In a significant proportion of patients, recurrent intracranial germinoma is curable by HDC without re-irradiation, provided that the disease remains sensitive to salvage chemotherapy.